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Objectives. This study reports the first multicenter experience
with the Wiktor coil stent for treatment of chronic total coronary
artery occlusions (CTOs).
Background. Percutaneous transluminal coronary angioplasty
(PTCA) of CTO is associated with very high restenosis and
reocclusion rates. Coronary stenting has been proposed as a
means of improving outcome. However, the Wiktor device for
CTOs has never been tested in a large patient sample.
Methods. From January 1993 to December 1996, 89 patients
with 91 CTOs underwent Wiktor stent implantation after success-
ful PTCA. The post-stenting regimen consisted of warfarin (Cou-
madin) plus aspirin in the initial 49 patients (55%) and aspirin
plus ticlopidine in 40 patients (45%).
Results. Stenting was successful in 87 patients (98%). At 1
month, 6% of patients had subacute stent thrombosis, 3% had a
major bleeding event, and 1% had access-site complications.
Subacute stent thrombosis showed univariate association with
warfarin therapy (p 5 0.009). Angiographic follow-up was ob-
tained in 76 (93%) of 82 eligible patients. The restenosis rate was
32%, including 4% reocclusions. By multiple logistic regression
analysis, restenosis was independently associated with multiple
stents (adjusted odds ratio [OR] 27.67, 95% confidence interval
[CI] 4.25 to 79.95, p 5 0.0008) and increasing values of occlusion
length (adjusted OR 1.23, 95% CI 1.09 to 1.39, p 5 0.001).
Freedom from death, myocardial infarction or stented vessel
revascularization was 87% and 72% at 1 and 3 years, respectively.
Conclusions. Short- and long-term clinical and angiographic
outcomes are favorable in patients undergoing Wiktor stent
implantation in CTO. Further technical improvement is needed to
reduce the restenosis rate in patients with long lesions and
multiple stents.
(J Am Coll Cardiol 1998;31:281–8)
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Chronic total coronary artery occlusions (CTOs) account for
10% to 20% of all percutaneous transluminal coronary angio-
plasty (PTCA) procedures at centers with high procedural
volumes, and these lesions pose a management dilemma for
the interventional cardiologist (1). Although substantial ad-
vances in PTCA devices and improvement in operators’ skill
have yielded a successful recanalization in ;80% of CTOs, a
restenosis rate of 44% to 77% limits the long-term benefit of
PTCA (1,2). Many patients with CTOs are therefore referred
for coronary artery bypass graft surgery (CABG), even in the
presence of single-vessel disease. Recently, coronary artery
stenting has emerged as a valuable therapeutic strategy for the
management of CTO (3–7). Intracoronary insertion of the
Palmaz-Schatz stent or the new, less shortening Wallstent after
successful PTCA of CTO has been associated with favorable
restenosis and reocclusion rates, improved anginal status and a
reduced need for late CABG (3–7). In the early 1990s, the
balloon-expandable, helicoid coil, low mass, radiopaque Wik-
tor stent became available for clinical investigation (8). This
device has been successfully used for restenotic lesions, bailout
situations, native coronary arteries and vein graft disease
(9–12). However, no study has so far tested the safety and
effectiveness of the Wiktor stent for treatment of CTO. This
study reports the short- and long-term clinical and angio-
graphic outcomes of Wiktor stent implantation in a large series
of patients with CTO.
Methods
Study patients. Between January 1993 and December
1996, 89 patients with 91 CTOs underwent Wiktor stent
implantation after successful recanalization by PTCA. Patients
were selected who had 1) angina pectoris with evidence of
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myocardial ischemia demonstrated by electrocardiographic
changes or positive results on stress testing; or 2) postinfarct
myocardial viability assessed either by dobutamine echocardi-
ography or thallium single-photon emission computed tomog-
raphy. Patients having had a previous revascularization proce-
dure (PTCA or CABG) or myocardial infarction (MI) within 1
month of the procedure were excluded. Lesion-related criteria
for exclusion were a reference diameter ,2.5 mm by visual
estimation and the presence of angiographically visible throm-
bus adjacent to the occlusion site. A CTO was defined as
complete interruption of the vessel, with either Thrombolysis
in Myocardial Infarction (TIMI) flow grade 0 (absolute occlu-
sion) or TIMI flow grade 1 (functional occlusion), that was .1
month old. The occlusion age was estimated either from the
date of MI in the distribution of the occluded vessel, abrupt
worsening of angina pectoris or information provided by
sequential angiograms when these were available. All patients
gave written, informed consent to the procedure. In addition,
at the time of initial stent implantation, patients were informed
about the need for 6-month angiographic and late clinical
follow-up. All patients included in this study had at least 12
months of follow-up.
Stent implantation procedure. Premedication consisted of
oral, non–enteric-coated aspirin, 325 mg/day, and calcium
channel blocking agents. A bolus of 10,000 U of heparin was
administered after sheath insertion with a repeat bolus given as
needed to maintain an activated clotting time .250 s. Patients
were not given dextran or dipyridamole before, during or after
the stent procedure. All patients underwent PTCA by a
standard technique in which the femoral approach was used.
The choice of guide wires, balloon type and brand and the
number and pressure of the inflations were left to the discre-
tion of the operator. Once the vessel was opened and the guide
wire was identified within the true lumen distal to the occlu-
sion, one or more Wiktor stents were implanted under fluoro-
scopic guidance with the aim to cover the entire lesion. The
Wiktor stent (Medtronic Inc.) is a balloon-expandable stent
composed of a single, loose-interdigitating, coil-like tantalum
wire (0.125 mm in diameter), formed into a sinusoidal wave
and configured as a helix. Tantalum confers good radiopacity.
The prosthesis, 14 to 16 mm long, is premounted on a
polyethylene semicompliant balloon. The maximal diameter of
the balloon during inflation determines the final size of the
prosthesis. The crimped stent profile is ;1.5 mm and deploy-
ment does not induce any modification in stent length. Stent
deployment was performed using an initial inflation of 8 atm.
Stent expansion was completed by additional inflations (max-
imal 14 atm), using the same balloon with the central marker
positioned at the distal and proximal ends of the device, until
good angiographic result was obtained. The result was consid-
ered inadequate if dissection flaps were not completely cov-
ered by stent struts. When multiple stents were required to
treat a long lesion or newly developed coronary dissection,
distal stents were usually placed first, but occasionally a single
proximal stent was placed first to eliminate the distal extension
of the false lumen. Overlapping or telescoping of sequential
stents was used only when additional radial support was
deemed advantageous; otherwise stents were implanted to
ensure minimal overlap and no gaps. Intravascular ultrasound
was not used to avoid possible damage of the Wiktor coil
during introduction of the ultrasound catheter. The angio-
graphic success of stenting was assessed off-line by a quantita-
tive estimate of residual coronary stenosis ,30% of the lumen
diameter within the stent, effectively positioned at the intended
site and by gradation of anterograde flow as a TIMI flow grade
3 perfusion.
Postprocedural medication protocol. The medication pro-
tocol was modified over the study period, after the publication
of newer guidelines for post-stent treatment. Until early 1994,
the first 49 patients (55%) were treated with standard postpro-
cedural anticoagulant therapy. In these patients, on comple-
tion of the procedure, heparin was discontinued briefly to
allow for sheath removal, then reinstituted within 3 to 4 h. Oral
anticoagulant therapy (warfarin sodium [Coumadin]) was ini-
tiated on the day of the procedure, and both heparin and
warfarin were continued until oral anticoagulation resulted in
prolongation of prothrombin time to an international normal-
ized ratio of 2.5 to 3.5, after which heparin was stopped.
warfarin was continued for 1 month in association with aspirin,
325 mg/day, which was given indefinitely. As of late 1994, the
subsequent 40 patients (45%) received no oral anticoagulant
agent. Heparin was discontinued 12 h after the intervention,
and ticlopidine, 250 mg twice daily, was started immediately
after the procedure and continued for 1 month in association
with aspirin, 325 mg/day, which was continued long term. For
all patients, nitrates and calcium channel blockers were rec-
ommended for at least 6 months.
Quantitative angiographic analysis. Cineangiographic
films were processed at a central core laboratory by two
experienced operators not involved in the stenting procedure.
Angiograms were quantitatively analyzed by the computer-
assisted Cardiovascular Measurement System (CMS-Medis
Medical Imaging Systems, Nuemen, The Netherlands), using
semiautomated edge detection. Intracoronary nitroglycerin
(0.1 to 0.2 mg) was injected before all angiographic assess-
ments. End-diastolic cine frames best displaying the lesion with
minimal foreshortening and overlay of side branches were
selected from among multiple projections and digitized. Quan-
titative analysis of the follow-up angiogram was performed by
using matching views. Absolute measurements were obtained
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
CTO 5 chronic total (coronary artery) occlusion
MI 5 myocardial infarction
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary angioplasty
SST 5 subacute stent thrombosis
TIMI 5 Thrombolysis in Myocardial Infarction
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using the dye-filled catheter (8F for intervention and 6F at
follow-up) as a scaling reference. The reference was measured
from angiographically normal segments adjacent to the lesion,
and the same reference segment was selected before and after
intervention and at follow-up. Late lumen loss was measured
as the difference between the minimal lumen diameter imme-
diately after stenting and that obtained at follow-up angiogra-
phy. The loss index was calculated as the ratio of late loss to
minimal lumen diameter after stenting. Occlusion length was
measured with manual calipers by using information from
ipsilateral or contralateral collateral penetration according to a
previously reported methodology (2). Measurements of lesion
length (in millimeters) were repeated by two operators on a
random sample of 45 studies and by the same observer on
different days without knowledge of earlier results. No system-
atic differences were noted between three paired measure-
ments (mean difference 0.70 6 5.09 mm, t 5 0.84, p 5 0.7).
Regression of the absolute difference between the length of
occlusion on its mean measurement yielded F 5 0.16 and p 5
0.8. Recorded angiographic characteristics included the mor-
phologic features of the occlusion (abrupt or tapered); the
presence of bridging collateral vessels; calcification on fluoros-
copy at the site of the occlusion; and evidence of coronary
dissection, defined as marked irregularity of the vessel wall, a
lumen filling defect suggestive of intimal flap or extravasation
of contrast agent outside the lumen after balloon dilation. Left
ventricular ejection fraction was determined by left ventricu-
lography performed with the use of biplane 30° right anterior
oblique and 60° left anterior oblique projections. A binary
definition of restenosis ($50% diameter stenosis occurring at
the stent site or immediately proximally or distally) and
reocclusion (TIMI flow grade 0 or 1) on follow-up angiography
was used.
Clinical and angiographic follow-up. Patients were fol-
lowed up by means of outpatient visits at intervals of 1, 3, 6 and
12 months and yearly thereafter. Telephone contact with the
patient or referring physicians was also used when needed for
follow-up purposes. Subacute stent thrombosis (SST) was
defined as a clinical event, leading to cardiac catheterization,
that identified stent vessel occlusion with TIMI flow grade 0 or
1 occurring .24 h and within 1 month of stent deployment.
Cardiac events were death, MI or requirement for target vessel
revascularization (CABG or PTCA), whichever occurred first.
If symptoms recurred before the scheduled 6-month follow-up
angiography, an angiogram was obtained earlier. If no definite
restenosis or reocclusion was present and the follow-up time
was ,4 months, the patient was asked to undergo further
coronary angiography at 6 months. The primary angiographic
end point of the study was the occurrence of restenosis,
including reocclusion, after 6 months of follow-up. Follow-up
was continued in patients who underwent repeat PTCA for
treatment of in-stent restenosis or reocclusion.
Statistics. Continuous measures are expressed as the mean
value 6 SD or as the median value and relative ranges;
dichotomous variables are presented as percentages. Compar-
ison of binary variables were performed using the Yates-
corrected chi-square statistic or, when appropriate, the Fisher
exact test. Continuous variables were compared by one-way
analysis of variance. Statistical significance (two-tailed) was
inferred at p , 0.05. Logistic regression analysis was separately
used to assess the contribution of clinical, angiographic and
procedural variables to two dichotomous outcomes (i.e., SST
and restenosis). Variables affecting restenosis were analyzed in
those patients who had angiographic follow-up available for
review. Univariate correlates were determined by logistic
regression analysis based on the maximum likelihood method.
To select covariates independently associated with each out-
come, significant univariate predictors were reassessed by
forward stepwise multivariate analysis, with values for inclu-
sion and elimination set at p 5 0.05 and p 5 0.10, respectively.
The likelihood-ratio chi-square value was used to assess mul-
tivariate model significance. As a measure of the strength of
the association between each multivariate predictor and the
outcome variable, an adjusted odds ratio (OR) with corre-
sponding 95% confidence intervals (CIs) was computed from
the estimated multiple logistic regression coefficient and stan-
dard error. Clinical events were described by the Kaplan-Meier
method.
Results
Baseline characteristics. The clinical features of the 89
study patients are presented in Table 1. Most patients were
middle-aged men. The majority of patients had severe angina
(Canadian Cardiovascular Society class $III), and over half
had previous MI. In 79% of patients, the estimated occlusion
age was .3 months. The angiographic and procedural vari-
ables are displayed in Table 2. A total of 91 lesions were
treated. Two patients had a total occlusion of both the left
anterior descending coronary artery and the right coronary
artery with controlateral collateral flow. Of all CTOs, 51%
were in the left anterior descending coronary artery distribu-
tion, with 34% and 15% in the right coronary artery and the
Table 1. Clinical Characteristics of the 89 Study Patients
Age (yr) 55 6 9
Male gender 66 (74)
Hypertension 35 (39)
Cholesterol .200 mg/dl 30 (34)
Diabetes mellitus 26 (29)
Cigarette smoking 48 (54)
CCS angina class $III 60 (67)
Previous MI 50 (56)
LVEF (%) 57 6 11
Multivessel disease 49 (55)
Estimated occlusion age
.1 to #3 months 19 (21)
.3 months 70 (79)
Warfarin therapy 49 (55)
Data are presented as mean value 6 SD or number (%) of patients. CCS 5
Canadian Cardiovascular Society; LVEF 5 left ventricular ejection fraction;
MI 5 myocardial infarction.
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left circumflex artery, respectively. Functional occlusions were
present in 27% of patients. The average length of occlusion
was 15.4 6 9.4 mm (median 16, range 4 to 47). A total of 148
Wiktor stents were implanted. Multiple stents were implanted
in 41 lesions (45%): 4 stents in 3 lesions, 3 stents in 10 and 2
stents in 28. The mean number of stents per lesion was 1.6. The
final minimal lumen diameter after stenting was 2.96 6
0.26 mm, with a percent residual stenosis of 13 6 10%. The
average nominal stent size was 3.40 6 0.35 mm. The nominal
stent size to vessel diameter ratio was 1.09 6 0.14 (median 1.0,
range 0.5 to 1.5). The mean final stent balloon-inflation
pressure was 11.9 6 1.6 atm.
Intraprocedural and short-term outcome. Of 89 patients,
stent implantation procedure was successfully performed in 87
(98%). In one patient stenting failed to cover a distal dissection
that extended outside the length of the stenosis. This patient
developed an angiographically documented acute stent occlu-
sion 16 h after the intervention, which was associated with a Q
wave MI, and subsequently underwent emergency CABG. In
the other patient, the stent was positioned in a left circumflex
artery but not at the site of the target lesion, which could not
be successfully crossed because of vessel tortuosity despite
satisfactory dilation. There were no instances of stent emboli-
zation or aborted attempts at stent delivery. No death or
cerebrovascular complication occurred during the hospital
stay. Short-term clinical follow-up was obtained in all patients
at 1 month of intervention. During that interval, major bleed-
ing events requiring blood transfusion occurred in 3 patients
(3%): gastrointestinal bleeding in two patients and macro-
scopic hematuria in one patient. Vascular access-site compli-
cations requiring surgical vascular repair developed in one
patient (1%) who showed a pseudoaneurysm on color flow
Doppler ultrasonography. Subacute stent thrombosis occurred
in five patients (6%) on days 4, 8, 11, 14 and 23. Two of these
patients had a nonfatal Q wave MI, one had a non–Q wave MI
and the remaining two complained of sudden onset of angina.
All patients underwent revascularization: PTCA in four pa-
tients and CABG in one. Remarkably, these five patients were
treated with warfarin, which had been discontinued before SST
in one patient (20%) because of bleeding complications. No
case of SST occurred in patients treated with ticlopidine and
aspirin or in patients with multiple stents.
Long-term follow-up. Of 82 patients with procedural suc-
cess and without SST, long-term clinical follow-up was
achieved in 100% at a mean time interval of 19 6 12 months
(range 2 to 44). Cardiac events occurred in 19 patients (23%).
There was one death (1%) at 8 months due to congestive heart
failure. Two patients (2%) had a nonfatal Q wave MI at 17 and
22 months, associated with in-stent restenosis in one and
reocclusion in the other. These two patients underwent PTCA
and CABG, respectively. Four patients developed unstable
angina, due to in-stent restenosis in three and reocclusion in
one. Two of these patients underwent CABG and two under-
went PTCA. Ten patients underwent stented vessel PTCA for
stable angina, due to restenosis at the stent site in nine patients
and reocclusion in one. Two further patients with stable angina
needed PTCA for new lesions in other vessels. The overall
incidence of stented vessel revascularization was 19% (n 5 16).
The Kaplan-Meier event-free survival curves, including cardiac
death, MI and stented vessel revascularization, are shown in
Figure 1. Events exclude those precipitated by other vessels in
patients with proven stent patency. The overall event-free
survival rate was 87% at 1 year and subsequently declined to
72%. Referral for repeat PTCA or CABG tended to take place
in the first 10 months after the procedure, with very little need
for revascularization thereafter. The 13 patients who had
repeat PTCA of the stented vessel remained asymptomatic at
a mean of 17 6 6 months after PTCA, with no further events,
except for one patient who died of documented bronchial
Figure 1. Freedom from death, MI and repeat stent vessel revascu-
larization after Wiktor stent implantation in CTO. Numbers in paren-
theses represent the number of patients at risk at each time interval.
Table 2. Angiographic and Procedural Variables of 91 Chronic
Total Coronary Artery Occlusions
Lesion location
LAD 46 (51)
LCx 14 (15)
RCA 31 (34)
Abrupt morphology 55 (60)
Bridging collateral vessels 16 (17)
Calcification on fluoroscopy 19 (21)
Functional occlusion (TIMI flow grade 1) 25 (27)
Occlusion length (mm) 15.4 6 9.4
Procedural dissection 31 (34)
Multiple stents 41 (45)
Reference diameter (mm)
Baseline 3.12 6 0.11
After stenting 3.11 6 0.21
MLD after stenting (mm) 2.96 6 0.26
DS after stenting (%) 13 6 10
Nominal stent size (mm) 3.40 6 0.35
Stent/vessel diameter ratio 1.09 6 0.14
Final stent balloon pressure (atm) 11.9 6 1.6
Data are presented as mean value 6 SD or number (%) of lesions. DS 5
diameter stenosis; LAD 5 left anterior descending coronary artery; LCx 5 left
circumflex coronary artery; MLD 5 minimal lumen diameter; RCA 5 right
coronary artery; TIMI 5 Thrombolysis In Myocardial Infarction.
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carcinoma. Angiographic follow-up was accomplished at a
mean of 6 6 3 months (range 2 to 11) after the intervention.
Control angiography was achieved in 76 (93%) of the 82
patients, as five asymptomatic patients declined the study and
one died. Quantitative angiographic analysis was performed in
76 lesions of 76 patients. Measurements of nonoccluded
segments documented a late lumen loss of 0.98 6 0.81 mm and
a loss index of 0.42 6 0.38. Restenosis was found in 24 patients
(32%) and 24 lesions (32%), including 3 reocclusions (4%).
Restenosis was observed in 18 of 35 lesions with multiple stents
and in 6 of 41 lesions with a single stent. Thus, the multiple
stent restenosis rate was 51%, significantly higher than the
15% rate for single stent (p 5 0.001). Of the 24 patients with
restenosis, 8 (33%) were asymptomatic and continued to
receive medical therapy owing to the absence of demonstrable
myocardial ischemia. A comparison of patients grouped ac-
cording to the occurrence of restenosis at follow-up angiogra-
phy is shown in Tables 3 and 4. No significant difference was
seen with regard to clinical variables, except for a greater use
of warfarin in the group with restenosis (71% vs. 40%, p 5
0.02). As for angiographic and procedural variables, patients
with restenosis had a significantly higher occlusion length
(27.2 6 6.3 mm vs. 13.2 6 5.1 mm, p , 0.005) and frequency
of multiple stents (75% vs. 33%, p , 0.005). The left anterior
descending coronary artery was more often stented in patients
with restenosis (63% vs. 37%, p 5 0.06).
Logistic regression analysis. Among the clinical, angio-
graphic and procedural variables examined (Table 1 and 2),
the single positive predictor of SST by univariate analysis was
warfarin therapy (chi-square 6.63, logistic regression coeffi-
cient [beta] 25.58, p 5 0.009). A significant negative correla-
tion of SST with either multiple stents (chi-square 5.52, beta
223.13, p 5 0.01) or final minimal lumen diameter after
stenting (chi-square 3.99, beta 24.06, p 5 0.04) was also
observed. However, when these variables were entered into
multiple logistic regression analysis, no specific clinical feature
or angiographic and procedural aspect was found to signifi-
cantly explain the occurrence of SST. Significant correlates of
restenosis are presented in Table 5. The final multivariate
model (chi-square 31.71, p , 0.00001) included two of these
variables. The strongest predictor of restenosis was multiple
stent implantation (adjusted OR 27.67, 95% CI 4.25 to 79.95,
p 5 0.0008); an independent association was noted also with
the length of the occlusion (adjusted OR 1.23, 95% CI 1.09 to
1.39, p 5 0.001).
Discussion
This study presents the first multicenter experience with a
coil stent for treatment of CTOs in the largest series of patients
reported to date. Our results demonstrate that intracoronary
Wiktor stent insertion can be safely and effectively performed
after successful recanalization of CTO and is associated with a
restenosis rate of 32% and very favorable long-term follow-up
findings.
Success of the intervention. Our procedural success rate
and immediate angiographic outcome match those achieved
with the Palmaz-Schatz stent and the Wallstent for treatment
of CTOs (3–7). The high delivery success rate and safety may
Table 3. Clinical Variables of Patients Grouped According to the
Occurrence of Restenosis
With
Restenosis
(n 5 24)
Without
Restenosis
(n 5 52)
p
Value
Age (yr) 57 6 8 58 6 11 NS
Male gender 17 (71) 41 (79) NS
Hypertension 9 (37) 17 (33) NS
Cholesterol .200 mg/dl 8 (33) 13 (25) NS
Diabetes mellitus 7 (29) 14 (27) NS
Cigarette smoking 13 (54) 27 (52) NS
CCS angina class $III 16 (67) 34 (65) NS
Previous MI 14 (58) 30 (58) NS
LVEF (%) 57 6 11 56 6 9 NS
Multivessel disease 13 (54) 27 (52) NS
Occlusion .3 mo 19 (79) 39 (75) NS
Warfarin therapy 17 (71) 21 (40) 0.02
Data are presented as mean value 6 SD or number (%) of patients.
Abbreviations as in Table 1.
Table 4. Angiographic and Procedural Variables in Patients
Grouped According to the Occurrence of Restenosis
With
Restenosis
(n 5 24)
Without
Restenosis
(n 5 52)
p
Value
Stented vessel
LAD 15 (63) 19 (37) 0.06
LCx 2 (8) 11 (21) NS
RCA 7 (29) 22 (42) NS
Abrupt morphology 14 (58) 31 (60) NS
Bridging collateral vessels 4 (17) 8 (15) NS
Calcification on fluoroscopy 5 (21) 10 (19) NS
Functional occlusion (TIMI flow
grade 1)
6 (25) 12 (23) NS
Occlusion length (mm) 27.2 6 6.3 13.2 6 5.1 ,0.005
Procedural dissection 9 (37) 17 (33) NS
Multiple stents 18 (75) 17 (33) ,0.005
Reference diameter (mm)
Baseline 3.12 6 0.23 3.10 6 0.33 NS
After stenting 3.10 6 0.21 3.09 6 0.25 NS
Follow-up 3.14 6 0.20 3.12 6 0.24 NS
MLD (mm)
After stenting 2.95 6 0.25 2.94 6 0.24 NS
Follow-up 0.96 6 0.33 1.99 6 0.31 ,0.005
DS (%)
After stenting 12 6 10 13 6 10 NS
Follow-up 68 6 17 27 6 12 ,0.005
Nominal stent size (mm) 3.40 6 0.37 3.40 6 0.36 NS
Stent/vessel diameter ratio 1.08 6 0.15 1.09 6 0.13 NS
Final stent balloon pressure (atm) 11.8 6 0.8 11.9 6 0.9 NS
Late lumen loss (mm) 1.99 6 0.30 0.95 6 0.32 ,0.005
Loss index 0.67 6 0.38 0.32 6 0.39 ,0.005
Data are presented as mean value 6 SD or number (%) of patients.
Abbreviations as in Tables 1 and 2.
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be explained by the low profile and longitudinal flexibility of
the Wiktor stent, which allow more natural bending and
tortuosity, factors that may be more favorable to dynamic
coronary flow. Correct positioning during fluoroscopy may be
easier with this tantalum stent in contrast to the scarcely visible
stainless-steel devices. Radiopacity facilitates deployment of
multiple stents exactly end to end with or without overlap for
the complete coverage of long coronary lesions and dissec-
tions. Because of its design, the Wiktor stent has been hypoth-
esized to have lower radial strength than other devices with a
more rigid and stiff mesh architecture. However, in vitro data
indicate that vascular support properties are not different for
some flexible coils and slotted tube stents (13). The Wiktor
stent, more recently tested by using the same in vitro model,
has shown a resistance to circumferential collapsing pressure
equivalent to that of the higher mass Gianturco-Roubin Flex-
Stent and even greater than the rigid Palmaz-Schatz stent
(Kirk N. Garratt, personal communication). Accordingly, ex-
perimental and clinical studies clearly indicate that the Wiktor
stent effectively scaffolds the instrumented vessel, with only
minimal elastic recoil, which does not contribute to late lumen
renarrowing or restenosis (11,14–16). In agreement with these
observations, coronary intervention with the Palmaz-Schatz
stent and Wiktor stent have demonstrated comparable imme-
diate and long-term angiographic benefits (17,18).
Short-term outcome. The incidence of SST (6%), vascular
access-site complications (2%) and major bleeding events
(3%) observed in the present study were lower than those
obtained with the Wiktor stent in bailout situations or re-
stenotic lesions (10–12). Chronic total coronary artery occlu-
sions are a well recognized thrombotic milieu, as mural
thrombosis is detected by angioscopy in most cases before and
after PTCA (19). The acceptable thrombotic occlusion rate in
the present study confirms the recent observation that elective
coronary stenting is an effective therapeutic strategy even for
patients with thrombus-laden lesions (20). The favorable short-
term results of the current study compare well with those
obtained with the Palmaz-Schatz stent in CTOs (3–6). Despite
the use of a slotted tube stent, these previous studies are
similar to ours in that neither high pressure postdilation
inflations nor systematic intracoronary ultrasound was utilized.
However, in the present study, a substantial proportion of
patients were managed with aspirin plus ticlopidine, a regimen
that has never been tested previously in patients with stented
CTOs. Notably, all of the patients with SST in our series were
receiving classic oral anticoagulation, which could favor plate-
let activation and subsequent thrombosis (21). Despite a
significant univariate association between warfarin therapy and
SST in our study, the lack of evidence in favor of an indepen-
dent relation may be due to the use of multiple regression
analysis with a low event rate. Nevertheless, our data are
consistent with recently published studies demonstrating that
patients who receive slotted tube or coil stents with optimal
angiographic results without intravascular ultrasound guidance
may be managed safely with a combination of aspirin and
ticlopidine without anticoagulation (22–25). Results of the Full
Anticoagulation Versus Aspirin-Ticlopidine (FANTASTIC)
randomized trial are also awaited to assess the risk/benefit
ratio of anticoagulation and to define optimal pharmacologic
treatment after coronary Wiktor stenting (26).
The adverse impact of coronary dissection on the risk of
SST after coil stent deployment has been documented previ-
ously (27). However, our study has not shown a specific
statistical association between procedural dissection and SST.
This may be attributed in part to multiple stent implantation,
which would allow the entire diseased segment to be ade-
quately covered and seems to have a protective effect with
respect to the occurrence of SST (negative correlation with the
event). Although there have been concerns that increased
exposure of metal may be more thrombogenic, several inves-
tigators have concluded that multiple stents do not enhance
the risk of SST when they are carefully deployed without
excessive overlapping (28–30). The loose interdigitating wire
design of the Wiktor stent accounts for ,10% of the total
vessel surface covered, which could limit its thrombotic poten-
tial (14). However, the issue of a possible lower SST and
vascular injury with a specific design or metal is an interesting
aspect that so far has only been addressed in experimental
models (31,32).
Long-term outcome. In this study, the long-term clinical
outcome, restenosis rate and predictors of restenosis of pa-
tients undergoing Wiktor stent implantation in CTOs are
presented. The restenosis and reocclusion rates in our study
compare favorably with those obtained with the Palmaz-Schatz
stent and Wallstent (3–7). The clinical outcome was also
satisfactory, with excellent overall survival and low event rates.
Over 3 years, only three patients (4%) required CABG. In
addition, the 13 patients who underwent repeat PTCA for
Table 5. Significant Correlates of Restenosis by Logistic Regression Analysis
Univariate Analysis Multivariate Analysis
Chi-Square Beta-Coeff p Value Adjusted OR 95% CI p Value
Warfarin therapy 6.23 1.27 0.018 — — —
Stented LAD 4.48 1.06 0.040 — — —
Occlusion length 10.02 0.10 0.003 1.23 1.09–1.39 0.001
Multiple stents 12.16 1.82 0.001 27.67 4.25–79.95 0.0008
Beta-Coeff 5 logistic regression coefficient; CI 5 confidence interval; LAD 5 left anterior descending coronary
artery; OR 5 odds ratio (adjusted for other variables in model).
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in-stent restenosis have been free of clinical recurrence at a
mean follow-up of 17 6 6 months. Thus, coronary surgery can
be avoided in most patients whose totally occluded vessels are
successfully stented. It is also interesting to note that 33% of
patients who met the angiographic criteria for restenosis were
asymptomatic and had no signs of inducible myocardial isch-
emia. These findings support the conclusion that borderline
lumen stent narrowing (60% to 70%) by quantitative coronary
angiography correlates poorly with both clinical symptoms and
prognosis (33). To reduce the likelihood of long-term failure of
stenting CTOs and possibly improve technical approaches for
managing such lesions, factors that predict the occurrence of
restenosis must be defined. According to our results, a long
occlusive lesion may confer a higher risk of restenosis after
stenting. This is in keeping with recent preliminary data that
outline the influence of lesion length and complexity on late
angiographic outcome and restenotic process after successful
coronary stent implantation (34,35). A plausible explanation of
this finding may be a significant residual plaque burden,
resulting from more severe and diffuse underlying atheroscle-
rosis, which is underestimated by angiographic lumen mea-
surements and may itself be a determinant of restenosis. In a
previous study by Goldberg et al. (4), the presence of a
moderate to severe dissection after Palmaz-Schatz stenting of
CTOs was the only significant variable associated with resten-
osis, but multiple stent implantation was not considered among
the angiographic and procedural predictors. Because multiple
stents were liberally used in our study for complete coverage of
dissections and long lesions, the relation between dissection
and restenosis may have been concealed. In our experience,
the implantation of multiple contiguous stents showed a very
strong independent association with restenosis. As already
observed in the early stent era, greater metal density and
repeat stent-on-stent trauma might impair passivation, pro-
mote thrombus formation and myointimal regrowth and
thereby increase the risk of restenosis (36). Despite major
advances in deployment techniques, our present observations
as well as very recent preliminary data from patients with
elective or nonelective coronary stenting (37,38) confirm the
relatively poor long-term outcome of multiple stents. However,
further studies are needed to clarify whether the use of
multiple stents yields the same long-term benefits demon-
strated with single stents.
Study limitations. This study did not compare coronary
stenting with conventional PTCA of CTOs. However, consid-
ering the high restenosis rate of 44% to 77%, including
reocclusion in 14% to 40% of patients, and a reintervention
rate .50% observed with PTCA alone (1,5–7), the addition of
an angioplasty control group would not have been cost-
effective and could have only confirmed the advantage of
stenting for this difficult clinical condition. Intracoronary ul-
trasound and high pressure balloon inflation to ensure optimal
stent expansion have been reported to improve the immediate
clinical outcome and reduce the frequency of SST in patients
receiving a Palmaz-Schatz stent (39). Because concerns exist
regarding crossing coil stents with current intravascular ultra-
sound devices and poorly profiled high pressure balloon cath-
eters (40), we did not use intravascular ultrasound and peak
balloon-inflation pressures were not particularly high. How-
ever, recent preliminary data suggest that high pressure bal-
loon dilation may increase late lumen loss after coronary
stenting (41,42). Despite implanting the stent in CTO, in which
one would expect a high late loss, we obtained a relatively low
loss index. This finding may testify to the benefit of moderate
pressure stent deployment, achieving a low residual stenosis
without creating excessive vessel wall injury. In addition,
preliminary data from a recently completed randomized study
with the Wiktor stent, in which routine high pressure balloon
inflations ($14 atm) were compared with “standard” pressure
inflations (8 atm) revealed that high pressure inflations in-
creased lumen dimensions (as assessed by intravascular ultra-
sonography) but did not improve the immediate and 6-month
clinical or angiographic outcomes, which were excellent in both
groups (43,44).
Conclusions. Our study points out the favorable short- and
long-term clinical and angiographic outcomes with the Wiktor
stent for treatment of CTOs. The high incidence of SST in the
warfarin group has decreased the rate of short-term successful
results, which might have been still better with the current, well
admitted management strategy (i.e., ticlopidine plus aspirin).
Although the use of multiple stents may increase the risk of
restenosis, this is offset by the low rate of SST owing to the
ability to completely cover coronary dissections. A second
generation of Wiktor stents with a short wave design and
heparin coating and the novel polymer-coated eluting Wiktor
stent (45) will probably help reduce SST and prevent resteno-
sis. Further refinements and improvements in stent implanta-
tion techniques for CTOs are needed to reduce restenosis in
patients with long lesions. However, the long-term clinical
results were favorable because most patients with restenosis
were successfully treated with repeat PTCA. These encourag-
ing findings provide evidence in support of elective Wiktor
stent implantation in CTO as a cost-effective procedure.
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